<DOC>
	<DOCNO>NCT02157272</DOCNO>
	<brief_summary>Primary Study Objective ( ) The primary objective demonstrate non-inferiority Rivaroxaban 20 mg ( 15mgqd case moderate renal insufficiency ) versus warfarin ( INR 2.0-3.0 ) respect occurrence cumulative end point incident acute thrombosis ( arterial venous ) confirm appropriate imaging study , major bleeding , death triple aPL-positive APS patient . Study Design A multicentre , interventional , prospective , parallel , randomised , control , open-label , Rivaroxaban 20 mg qd ( 15mg qd patient moderate renal insufficiency ) v warfarin ( INR target 2.5 ) , non-inferiority study , 535 triple aPL-positive APS patient approximately 40 Internal Medicine Thrombosis centre . Each local Institutional Review Board approve study . Study Population Patients sex , age 18-75 , affected anti-phospholipid syndrome , high probability recurrence define triple aPL-positivity , eligible study . Primary Outcome variables The primary cumulative outcome measure incident acute thrombosis ( arterial venous ) confirm appropriate imaging study , major bleeding , death . Secondary Outcome variable Separate evaluation arterial venous thrombosis all-cause death . 04.27.2015 : An amendment make . Enrollment permit till 75 year age .</brief_summary>
	<brief_title>Rivaroxaban Thrombotic Antiphospholipid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Signed date informed consent form 2 . Male female age 1875 year 3 . Triple aPLpositivity last blood sample define : aCL IgG/M ( ≥40 GPL MPL , mediumtohigh titer , and/or great 99th percentile ) aB2GPI IgG/M ( ≥40 U , mediumtohigh titer , and/or great 99th percentile ) LA test positive base International Society Thrombosis &amp; Hemostasis Recommendations . Positivity aCL abeta2GPI must isotype . To confirm triple positivity aPL validate laboratory diagnosis , plasma ( least 2ml prepared double centrifugation 2000g ) patient Center store 80°C later send dry ice retested reference laboratory ( Padua Thrombosis Centre ) . Expenses shipment charge coordinator Center . 4 . History thrombosis ( objectively prove arterial , venous , and/or biopsy proven microthrombosis ) and/or pregnancy morbidity accord Miyaki Subjects meeting follow criterion enrol study : 1 . Severe hypersensitivity reaction rivaroxaban 2 . Calculated CLCR &lt; 30 mL/min screen visit 3 . Current pregnancy breast feeding . Pregnancy highly discourage patient programmed patient exclude study . If sexually active , practice effective method birth control ( e.g. , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study 4 . Concomitant treatment anticoagulant , unfractionated heparin , low molecular weight heparin ( enoxaparin , dalteparin , etc . ) heparin derivative ( fondaparinux ) , oral anticoagulant ( dabigatran etexilate , apixaban ) case substitute study drug . 5 . Patients take interfering medication : pharmacologic interaction may occur strong inhibitor pglycoprotein CYP3A4 , e.g. , azoleantimycotics , ketoconazole , itraconazole , voriconazole , posaconazole , HIV protease inhibitor ; coadministration rivaroxaban therefore contraindicate case . Several drug use neurological patient , phenobarbital , phenytoin , carbamazepine , st john 's wort ( hypericum ) , pglycoprotein inducer avoid . Whenever possible , would better use levetiracetam topiramate antiepileptic therapy . 6 . Hemorrhage RiskRelated Criteria History condition associate increase bleed risk include , limit : Major surgical procedure trauma within 30 day randomization visit Clinically significant gastrointestinal bleeding within 6 month randomization visit History intracranial , intraocular , spinal , atraumatic intraarticular bleed Chronic hemorrhagic disorder Known intracranial neoplasm , arteriovenous malformation , aneurysm Planned invasive procedure potential uncontrolled bleeding . Sustained uncontrolled hypertension : systolic blood pressure ≥180 mmHg 7 . Known liver cirrhosis ALT three time upper normal value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Antiphospholipid</keyword>
	<keyword>Syndrome</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Treatment</keyword>
</DOC>